EGFR and non-small cell lung carcinoma: This review recapitulates the underlying mechanisms contributing to the inferior clinical outcomes of anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICIs) in NSCLC patients bearing EGFR mutations.